genz

French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right that represents potential future payments if Lemtrada, the company's multiple sclerosis drug, is a...

General Motors (GM) most likely has just a few days before it files for bankruptcy, marking the final death gasps of a company that once controlled 50 percent of the North American vehicle market and sported a peak market value (in April 2000) of $54 billion. As I've posted, GM's $74 billion in...